Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 2851–2900 of 76231
On May 18, 2026, Diego Miralles, M.D. resigned as a member of the Board of Directors (the “Board”) of Artiva Biotherapeutics, Inc. (the “Company”), effective May 18, 2026
On May 18, 2026 (the “Effective Date”), Fred Aslan, M.D. resigned as President of the Company in connection with Dr. Miralles’s appointment as President and Head of Research and Development of the Company as described below.
On May 18, 2026, Thad Huston and the Company agreed to Mr. Huston’s separation from his position as Chief Financial Officer and principal financial and accounting officer of the Company, effective May 22, 2026
On May 15, 2026, Mr. Bryan Pechersky, Executive Vice President, General Counsel and Corporate Secretary of Upbound Group, Inc. (the “Company”), notified the Company of his resignation from the Company, effective on June 5, 2026.
Simona Skerjanec, who has been serving as Interim Chairperson since February 2026, will transition from Interim Chairperson and continue to serve as a member of the Board.
appointed Michael W. Bonney as Chair of the Board, effective immediately.
On March 18, 2026, Steve Chen resigned as a director of SolarMax Technology, Inc. (the “Company”) for reasons of health.
On May 13, 2026, in connection with the IPO, Jonathan Cole, Jody Sitkoski, and Susie Kuan (together with Gus Garcia, Lewis Silberman and Anantha Ramamurti, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
On May 13, 2026, in connection with the IPO, Jonathan Cole, Jody Sitkoski, and Susie Kuan (together with Gus Garcia, Lewis Silberman and Anantha Ramamurti, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
On May 13, 2026, in connection with the IPO, Jonathan Cole, Jody Sitkoski, and Susie Kuan (together with Gus Garcia, Lewis Silberman and Anantha Ramamurti, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
On May 14, 2026, in connection with the IPO, Eyal Waldman, David DeWalt and Paul Hodermarsky (the “ New Directors ” and, collectively with Tom Y. Livne and Matthew J. Norden, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
On May 14, 2026, in connection with the IPO, Eyal Waldman, David DeWalt and Paul Hodermarsky (the “ New Directors ” and, collectively with Tom Y. Livne and Matthew J. Norden, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
On May 14, 2026, in connection with the IPO, Eyal Waldman, David DeWalt and Paul Hodermarsky (the “ New Directors ” and, collectively with Tom Y. Livne and Matthew J. Norden, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
On May 18, 2026, Scott Cundy was appointed to serve as a director of the Board, effective July 3, 2026, to fill the vacancy resulting from Mr. Wall’s departure.
On May 17, 2026, Brett Wall, a class II director of the Board of Directors (the “Board”) of MiniMed Group, Inc. (“MiniMed”) and member of the Board’s Nominating and Corporate Governance Committee, notified the Board that he will resign from the Board effective July 3, 2026.
Richard Raffetto, Senior Executive Vice President and President of Commercial and Private Banking of the Bank, and Lee Smith, Senior Executive Vice President and Chief Financial Officer of the Bank, will serve as Co-Presidents and Co-Chief Operating Officers of the Bank, effective immediately.
Bao Nguyen, Senior Executive Vice President, General Counsel and Chief of Staff of the Bank, will become the Bank’s Chief Legal Officer and remain Chief of Staff
Peter Sullivan, Senior Deputy General Counsel and Chief Regulatory Counsel of the Bank, will become the Bank’s General Counsel
Joseph M. Otting, Executive Chairman, President, and Chief Executive Officer, will relinquish the title and role of President, while continuing to serve as Executive Chairman and Chief Executive Officer
Richard Raffetto, Senior Executive Vice President and President of Commercial and Private Banking of the Bank, and Lee Smith, Senior Executive Vice President and Chief Financial Officer of the Bank, will serve as Co-Presidents and Co-Chief Operating Officers of the Bank, effective immediately.
On May 12, 2026, in connection with the IPO, James Barresi, Robert Jones, Michael Taff and Joseph V. Topper, Jr. (collectively with Thomas Cestare and Jack Kopnisky, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
On May 12, 2026, in connection with the IPO, James Barresi, Robert Jones, Michael Taff and Joseph V. Topper, Jr. (collectively with Thomas Cestare and Jack Kopnisky, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
On May 12, 2026, in connection with the IPO, James Barresi, Robert Jones, Michael Taff and Joseph V. Topper, Jr. (collectively with Thomas Cestare and Jack Kopnisky, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
On May 12, 2026, in connection with the IPO, James Barresi, Robert Jones, Michael Taff and Joseph V. Topper, Jr. (collectively with Thomas Cestare and Jack Kopnisky, the “ Directors ”) were appointed to the board of directors of the Company (the “ Board ”).
As previously reported, William F. Gifford, Jr. retired as Altria’s CEO effective upon the conclusion of the Annual Meeting.
As previously reported, Salvatore Mancuso was elected Chief Executive Officer (“CEO”) of Altria Group, Inc. (“Altria”) effective upon the conclusion of Altria’s Annual Meeting of Shareholders held on May 14, 2026
Also as previously reported, Heather A. Newman was elected Executive Vice President and Chief Financial Officer of Altria effective upon the conclusion of the Annual Meeting.
On May 18, 2026, Limbach Holdings, Inc. (the “Company”) announced that it has appointed Michael J. Reed to serve as the Company’s Executive Vice President and Chief Operating Officer, effective as of May 18, 2026
On May 13, 2026, the Board of Directors (the “Board”) of 60 Degrees Pharmaceuticals, Inc. (the “Company”) appointed Eric Francois to serve as a member of the Board, effective immediately.
Jill Olmstead will be leaving her role as the Chief Human Resources Officer of LendingTree, LLC (together with LendingTree, Inc., the “Company”), and her employment will be terminated without cause effective May 31, 2026
Simon Keeton, the former Group President, Power Solutions Group, of onsemi, stepped down from all officer positions with onsemi effective March 9, 2026, as mutually agreed between the parties.
Brett Wall will be departing from his position as Executive Vice President and President, Neuroscience Portfolio
Dr. Kweli Thompson, currently Senior Vice President and President, Cardiac Rhythm Management, will be assuming the role of Executive Vice President and President, Neuroscience Portfolio, effective June 1, 2026.
On May 13, 2026, the Board of Directors of Aspen Aerogels, Inc. (the “Company”) designated Grant Thoele as the Company’s principal accounting officer, effective immediately, in addition to his current roles as the Company’s Chief Financial Officer, Treasurer and principal financial officer.
On May 15, 2026, the Board of Directors (the “Board”) of Ashland Inc. (the “Company”) increased the size of the Board from eight to nine directors and appointed Mr. Bertrand Loy to serve as an independent director on the Board, effective the same day.
We are sorry to inform our shareholders and the public in general of the passing of Mr. James F. O’Rourke, our beloved President and Director of Powerdyne International Inc.
and (ii) Maryellen Emerson as Vice-President and Secretary and elected her to serve as a director of the Company until the next annual meeting of the shareholders.
On May 12, the past members of the Board of Directors of Powerdyne International, Inc. (the “Company”) appointed (i) Anthony Carchide as President and Chief Financial Officer and elected him to serve as a director of the Company until the next annual meeting of the shareholders
On May 18, 2026, the board of directors (the “Board”) of Penguin Solutions, Inc. (the “Company”) increased the authorized size of the Board to eight members, and upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed David Heard to the Board and as a member of the Compensation Committee of the Board, effective immediately.
On May 12, 2026, Derek Small and Mark DiPaolo Esq. tendered their resignations from the Board of Directors of Innoviva, Inc.
On May 18, 2026, following the resignations of Messrs. Small and DiPaolo, the Board elected Josephine Linden to serve as a member of the Board of Directors (the “Linden Effective Date”).
On May 12, 2026, Derek Small and Mark DiPaolo Esq. tendered their resignations from the Board of Directors of Innoviva, Inc.
On May 14, 2026, Guy M. Erwin II was named to serve as Senior Vice President – Chief Accounting Officer of FedEx Freight Holding Company, Inc. (“FedEx Freight” or the “Company”) beginning on June 1, 2026.
the Board of Directors appointed Craig Wilson, the Company’s Vice President of Finance and Accounting, to serve as Executive Vice President and Chief Financial Officer of the Company, effective May 14, 2026.
announced that James Richardson had stepped down from his role as Executive Vice President and Chief Financial Officer of the Company.
Effective May 18, 2026, Aixin Life International, Inc. (the “Company”) accepted the resignation of Mr. Xinliang Li a/k/a Christopher Lee from the Company’s Board of Directors.
On May 14, 2026, in connection with the IPO, Sam Lynn, Darla K. Anderson and Constance K. Weaver were appointed to the board of directors of the Company.
On May 14, 2026, in connection with the IPO, Sam Lynn, Darla K. Anderson and Constance K. Weaver were appointed to the board of directors of the Company.
On May 14, 2026, in connection with the IPO, Sam Lynn, Darla K. Anderson and Constance K. Weaver were appointed to the board of directors of the Company.
On May 17, 2026, Stefan D. Loren, Ph.D. notified the board of directors (the “Board”) of Cellectar Biosciences, Inc. (the “Company”), that he does not intend to stand for reelection as a Class III director at the upcoming 2026 annual meeting of the stockholders of the Company (the “Annual Meeting”), at which time his current term as a director will expire.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.